title: Current developments in malaria transmission-blocking vaccines.
abstract: Malaria is still a leading cause of morbidity and mortality in human populations. Problems, including drug-resistant parasites and insecticide resistant mosquitoes, ensure the continued hold of malaria in the tropics and sub-tropics. Each year around 100 million cases of malaria result in at least 50,000 deaths outside of sub-Saharan Africa; within sub-Saharan Africa itself, malaria causes around one million child deaths per year. New approaches for malaria control are badly needed and much effort has gone to develop malaria vaccines. In addition to giving personal protection, most such vaccines would also tend to reduce the transmission of malaria. One class of vaccine is being developed specifically for this purpose--the malaria transmission-blocking vaccines (TBV). TBVs are based upon antigens expressed on the surface of the sexual and mosquito mid-gut stages of malaria parasites. These antigens are the targets of antibodies induced by vaccination of the host and ingested with the parasites in a mosquito blood meal. The antibodies act by inhibiting the parasite's development within the mosquito itself and they thereby prevent the onward transmission of the parasites. TBVs could contribute to the total interruption of malaria transmission in many locations with relatively low transmission rates, mostly outside sub-Saharan Africa. Under almost all transmission rates, however, TBVs would help reduce malaria incidence and malaria-related morbidity and mortality. Promising recombinant TBV candidate antigens for the two main human malaria parasite species, Plasmodium falciparum and Plasmodium vivax, have been produced and tested in the laboratory; one has undergone early clinical trials.
authors.affiliation: Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, NIAID/NIH, 5640 Fishers Lane, Rockville, MD 20852, USA.
authors.forename: A
authors.initials: A
authors.lastname: Stowers
authors.forename: R
authors.initials: R
authors.lastname: Carter
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D002648:Child; D009033:Culicidae / Q000469:parasitology / Q000502:physiology; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000635:transmission; D017780:Malaria Vaccines / Q000737:chemistry / Q000276:immunology*; D010963:Plasmodium falciparum / Q000276:immunology* / Q000502:physiology; D010966:Plasmodium vivax / Q000276:immunology* / Q000502:physiology; D015800:Protozoan Proteins / Q000276:immunology; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D000953:Antigens, Protozoan; D000954:Antigens, Surface; D017780:Malaria Vaccines; C071284:Pfs25 protein, Plasmodium falciparum; D015800:Protozoan Proteins; C121473:Pvs25 protein, P vivax; D011994:Recombinant Proteins